NextCell Pharma (Sweden) Performance
| NXTCL Stock | SEK 2.80 0.16 5.41% |
The company secures a Beta (Market Risk) of 0.47, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NextCell Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding NextCell Pharma is expected to be smaller as well. At this point, NextCell Pharma AB has a negative expected return of -0.0144%. Please make sure to verify NextCell Pharma's semi variance, as well as the relationship between the daily balance of power and period momentum indicator , to decide if NextCell Pharma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days NextCell Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, NextCell Pharma is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 139.2 M | |
| Total Cashflows From Investing Activities | -9.3 M |
NextCell |
NextCell Pharma Relative Risk vs. Return Landscape
If you would invest 298.00 in NextCell Pharma AB on December 24, 2024 and sell it today you would lose (18.00) from holding NextCell Pharma AB or give up 6.04% of portfolio value over 90 days. NextCell Pharma AB is generating negative expected returns and assumes 4.2857% volatility on return distribution over the 90 days horizon. Simply put, 38% of stocks are less volatile than NextCell, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
NextCell Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NextCell Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NextCell Pharma AB, and traders can use it to determine the average amount a NextCell Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0034
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NXTCL |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NextCell Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NextCell Pharma by adding NextCell Pharma to a well-diversified portfolio.
NextCell Pharma Fundamentals Growth
NextCell Stock prices reflect investors' perceptions of the future prospects and financial health of NextCell Pharma, and NextCell Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NextCell Stock performance.
| Return On Equity | -0.3 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (4.75) % | |||
| Current Valuation | 134.94 M | |||
| Shares Outstanding | 34.38 M | |||
| Price To Book | 2.01 X | |||
| Price To Sales | 37.14 X | |||
| Revenue | 5.59 M | |||
| EBITDA | (34.08 M) | |||
| Cash And Equivalents | 150.75 M | |||
| Cash Per Share | 4.39 X | |||
| Book Value Per Share | 3.10 X | |||
| Cash Flow From Operations | (33.31 M) | |||
| Earnings Per Share | (0.81) X | |||
| Total Asset | 124.66 M | |||
About NextCell Pharma Performance
Assessing NextCell Pharma's fundamental ratios provides investors with valuable insights into NextCell Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the NextCell Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden. NextCell Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 10 people.Things to note about NextCell Pharma AB performance evaluation
Checking the ongoing alerts about NextCell Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NextCell Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NextCell Pharma AB generated a negative expected return over the last 90 days | |
| NextCell Pharma AB has high historical volatility and very poor performance | |
| NextCell Pharma AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 5.59 M. Net Loss for the year was (35.02 M) with loss before overhead, payroll, taxes, and interest of (2.49 M). | |
| NextCell Pharma AB has accumulated about 150.75 M in cash with (33.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 43.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing NextCell Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NextCell Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NextCell Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NextCell Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NextCell Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NextCell Pharma's stock. These opinions can provide insight into NextCell Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.